ReviewCurrent oncology reports2020
Advances in the Management of Pediatric Sarcomas.
Review in Current oncology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 19 citations in OpenAlex.
- Prevalence and Risk Factors for Financial Toxicity Among Sarcoma Patients During and Following Treatment Across the Lifespan.Cancer reports (Hoboken, N.J.) · 2026Article
- Pediatric sarcomas: challenges and opportunities.Genes & development · 2026Review
- The investigational anti-B7-H3 antibody-drug conjugate vobramitamab duocarmazine exerts anti-tumor activity in vitro and in vivo in pediatric sarcoma preclinical models.Cell death & disease · 2026Article
- Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR.Clinical and translational medicine · 2025Article
- Developing CAR T-Cell Therapies for Pediatric Solid Tumors.Paediatric drugs · 2025Review
- Pediatric tonsillar synovial sarcoma: extremely rare case report.Frontiers in pediatrics · 2025Article
- BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway.Journal of bone oncology · 2024Article
- Identification of an ADME-related gene for forecasting the prognosis and responding to immunotherapy in sarcomas.European journal of medical research · 2024Article
- Breaking down the tumor immune infiltration within pediatric sarcomas.Frontiers in endocrinology · 2023Review
- A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma.Frontiers in immunology · 2023Article
- In vivo 3D profiling of site-specific human cancer cell morphotypes in zebrafish.The Journal of cell biology · 2022Article
- Clinical Perspectives forMetabolites · 2022Review
- Identification of a novel gene signature with regard to ferroptosis, prognosis prediction, and immune microenvironment in osteosarcoma.Frontiers in genetics · 2022Article
- Association between biologically effective dose and local control after stereotactic body radiotherapy for metastatic sarcoma.Journal of radiosurgery and SBRT · 2022Article
- Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality.Frontiers in immunology · 2022Review
- Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment.Frontiers in oncology · 2022Review
- Introducing Fluorescence-Guided Surgery for Pediatric Ewing, Osteo-, and Rhabdomyosarcomas: A Literature Review.Biomedicines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe prognosis of pediatric patients who present with metastatic or recurrent sarcomas remains poor. In this review, we summarize the advances in the management of metastatic and relapsed pediatric sarcoma by highlighting recent and future clinical trials. RECENT
findingsResearch into the identification of novel therapies for refractory pediatric sarcomas continues to advance. Outcomes have not improved in several decades underlying a need for improved understanding of the biology behind these tumors and the identification of novel therapeutic molecular targets that can be exploited pharmacologically. Multiple challenges remain for novel therapy in sarcomas such as the selection of effective targets, management of toxicities, and the tumor microenvironment. Many unique challenges remain in the treatment of patients with refractory pediatric sarcomas. Multiple strategies and targets are under investigation that hold promise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.